Document is current
Any future updates will be listed below
-
Authors
Morganti, Stefania
Khan, Rabia A.
Berrocal-Almanza, Luis C.
Miranda, Miguel
Luo, Linlin
Xu, Xiaoqing
Partridge, Ann H.
Lynce, Filipa
-
Funding
Funding for this research was provided by:
AstraZeneca UK Plc
Merck Sharp & Dohme Corp.
- License Information
-
More Information
Article History
Received: 15 November 2024
Accepted: 12 March 2025
First Online: 15 April 2025
Declarations
:
: Filipa Lynce has served on advisory boards for AstraZeneca and Pfizer. She has also received research funding from AstraZeneca. Stefania Morganti is supported by the Italian Association for Cancer Research (AIRC) and Fondazione Gianni Bonadonna, and she has received support from AstraZeneca and Menarini/Stemline. Rabia A. Khan was contracted to AstraZeneca at the time of the study and is currently affiliated with Analysis and Intelligence Assessment, UK Health Security Agency, London, UK and the Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Luis C. Berrocal-Almanza is currently affiliated with AstraZeneca Global Patient Safety, Luton, UK. Luis C. Berrocal-Almanza, Miguel Miranda, Linlin Luo, and Xiaoqing Xu are employees of AstraZeneca and hold shares. Ann H. Partridge has no conflicts of interest to declare.
: Per guidance from the U.S. Department of Health and Human Services and National Institutes of Health, ethics approval was not required as this study utilized deidentified patient data.
